Part C: Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)
Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry
In the expansion cohort: subjects must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; bone lesions are not considered measurable by definition
Bony metastatic lesions must be =< 8 cm in maximum dimension and evaluable on either a computed tomography (CT) or magnetic resonance imaging (MRI) scan; metastatic lesions in the spine must involve =< 3 contiguous vertebral bodies
At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version 1.1
Have undergone magnetic resonance imaging (MRI) for MB, a computerized tomography (CT) / metaiodobenzylguanidine (MIBG) scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month prior to first dose of study treatment
Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Post-operative computed tomography (CT) myelogram or magnetic resonance imaging (MRI) perfusion with evidence of separation of tumor and the spinal cord
The subject has had an assessment of all known non-CNS disease sites e.g., by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
At least 1 measurable lesion as defined by RECIST 1.1 on imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI])
All patients must have measurable disease documented by computed tomography (CT), magnetic resonance imaging (MRI), or nonmeasurable disease documented by physical exam within 28 days prior to registration
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 28 days before the first dose of cabozantinib
Hepatocellular carcinoma (HCC) diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs 5 per the American College of Radiology [ACR’s] LIRADs criteria) by computed tomography (CT) or magnetic resonance imaging (MRI)
Has 1 or more discrete malignant lesions that are amenable to ?2 separate biopsies guided by one of the following modalities: visual inspection, ultrasound guidance, or cross sectional image guidance (computed tomography/magnetic resonance imaging [CT/MRI]).
Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v1.1.
Must be able to tolerate computed tomography (CT) and/or magnetic resonance imaging (MRI) with contrast
Metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
Tumor thickness is 4 mm or less (measured clinically and/or by computed tomography [CT] or magnetic resonance imaging [MRI] scan)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 that can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan
Individuals with distant metastases or clinically or pathologically involved lymph nodes are ineligible; if suspected, they must be ruled out by computed tomography (CT), pelvic magnetic resonance imaging (MRI), or bone scan within 365 days of study entry
Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1
Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
At least one lesion that can be accurately assessed at baseline by computed tomography (TC), magnetic resonance imaging (MRI) or X-ray, that is suitable for repeated measurement, OR
Evidence of metastatic disease on imaging studies (computed tomography [CT] and/or bone scan)
Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography [CT] scan or magnetic resonance imaging [MRI])
Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
Must be found to have locally advanced unresectable disease following standard chemotherapy and/or (+/-) radiotherapy as demonstrated with computed tomography (CT)/magnetic resonance imaging (MRI) and surgical evaluation
Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on computed tomography [CT] scan and/or magnetic resonance imaging [MRI] of the abdomen and pelvis)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI).
Magnetic resonance imaging (MRI) pelvis, computed tomography (CT) pelvic, or bone scan for a PSA >= 0.2 ngs/ml may be done, based on the physician preference
Six or more metastases on diagnostic or treatment planning imaging, which include either computed tomography (CT) or magnetic resonance (MR) imaging.
Metastatic disease documented by at least one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI)
Evidence of metastasis by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histologic confirmation
Subject has at least 1 measurable lesion per RECIST v1.1 criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
Metastatic disease evident on computed tomography (CT) or magnetic resonance imaging (MRI) staging scans
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Patient must have recent imaging (computed tomography [CT] or magnetic resonance imaging [MRI], as appropriate) within 4 weeks of trial enrollment, demonstrating measurable disease as defined by RECIST 1.1.
Radiographic confirmation of oligometastatic diagnosis via bone scan validated by either computed tomography (CT) scan or magnetic resonance imaging (MRI) within the past 90 days
Unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or have documented recurrent glioma on diagnostic biopsy
Patients with a parenchymal brain lesion thought to be consistent with active lymphoma on screening computed tomography/magnetic resonance imaging (CT/MRI); of note, patients with cerebral spinal fluid (CSF) involvement alone are not excluded
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans).
Evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable FDG-avid lesions on PET)
Patients must have imaging (magnetic resonance imaging [MRI] or computed tomography [CT] abdomen liver protocol) confirmed hepatocellular carcinoma. Patients cannot have metastatic HCC
Measurable disease, even after resection of applicable lesion for TIL harvest; defined as >= 1 lesion that is >= 10 mm in one dimension by computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers on clinical exam
Measurable disease by RECIST v1.1 criteria (tumor >= 1 cm in longest diameter on axial image on computed tomography (CT) or magnetic resonance imaging (MRI) and/or lymph node(s) >= 1.5 cm in short axis on CT or magnetic resonance imaging [MRI]) on baseline imaging
Evidence of metastatic disease to the bone seen on most recent bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Has measurable disease as defined by RECIST 1.12 on computed tomography (CT) or magnetic resonance imaging (MRI) and as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Gross disease apparent on imaging (magnetic resonance imaging [MRI] or computed tomography [CT])
Patients must have at least one lesion that is not within a previously radiated field and that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scans per RECIST version 1.1; bone lesions are not considered measurable
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
Active disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
>= 1 evaluable site of disease measuring >= 1.5 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) as measured per Response Evaluation Criteria in Solid Tumors (RECIST)
Bone disease documented by either: a positive bone scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI); or biopsy proven bony metastases
At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.
COHORT 2 (ON PROGRESSION OF SORAFEINIB): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on computed tomography/magnetic resonance imaging (CT/MRI); prior surgery or local therapy within 4 weeks prior to cycle 1 day 1, with the exception of palliative radiation therapy to the bone
Evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computed tomography (CT) scan; subjects with resolving hemorrhage changes, punctuate hemorrhage, or hemosiderin are eligible
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Clinical stage T3 or less as demonstrated by computed tomography (CT)/magnetic resonance imaging (MRI) will be selected as the prostate is resectable
Patients must have potentially resectable pancreatic carcinoma and have agreed to undergo surgical resection at Monroe Dunaway (MD) Anderson Cancer Center if operable; they will have undergone staging (physical examination, contrast enhanced computed tomography [CT] or magnetic resonance imaging [MRI] [if CT contraindicated] to determine resectability)
Unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes
No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to registration
Patients with evidence of an acute intracranial or intratumoral hemorrhage on computed tomography (CT) or magnetic resonance imaging (MRI) are not eligible (patients with evidence of resolving hemorrhage will be eligible)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
All patients positive for invasion must have imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI]) documenting normal upper urinary tracts and absence of locally advanced bladder cancer within 60 days prior to study registration
Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
Patients must be willing to undergo a radiologic scan (computed tomography [CT] or magnetic resonance imaging [MRI], depending on organ involved) after last drug dose and prior to minimally-invasive surgery
At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib.
At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI]) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion >= 10 mm in longest diameter
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans)
Has staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within 4 weeks prior to treatment initiation
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated), and if the patients with CNS metastases are not taking prednisone > 10 mg or equivalent daily
Patients must have measurable disease, by computed tomography (CT) or magnetic resonance imaging (MRI) per modified RECIST criteria for mesothelioma; radiographic tumor assessment must be performed within 28 days prior to the first treatment
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)
No evidence of > grade 1 active CNS hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
Localized spine metastasis from the cervical (C)1 to lumbar (L)5 levels with documented epidural cord compression by a screening imaging study (magnetic resonance imaging [MRI] or computed tomography [CT] myelogram); site may have a maximal involvement of 2 contiguous vertebral bodies; patients with other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible
Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria; the criteria specifies computed tomography (CT) or magnetic resonance imaging (MRI) intense arterial uptake followed by “washout” of contrast in the venous-delayed phases; any atypical lesions must be confirmed by biopsy
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])
Patient must have measurable disease\r\n* Tumor size at least >= 5 cm in the longest diameter as measured by computed tomography (CT) scan or magnetic resonance imaging (MRI) for which radiation is feasible
Evidence of metastatic disease: minimum imaging required Computed tomography scan (CT) / Magnetic Resonance Imaging (MRI) and Whole Body Bone Scan (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
Adult patients with locally advanced or recurrent orbital or periorbital BCCA, or a medial canthal BCCA that threatens the lacrimal drainage system, as noted by clinical exam, clinical photography, computed tomography (CT) or magnetic resonance imaging (MRI) and positive biopsy, and who do not have a contraindication to either surgical or vismodegib treatment\r\n* Treating physician to assess whether the patient is a candidate for vismodegib treatment
Participants must have evaluable or measurable disease based on RECIST 1.1 using computed tomography (CT)/magnetic resonance imaging (MRI).
Clinically confirmed brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI) criteria; if there is evidence of extra-cranial metastatic disease, it is preferable if that the lesions be pathologically confirmed and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility
Patients may not be on systemic steroids within 4 weeks of enrolling on study with the exception of physiologic replacement doses (for instance in the case of adrenal insufficiency) or steroid premedication for baseline magnetic resonance imaging (MRI) and/or computed tomography (CT) in the case of subjects with known contrast dye allergies
Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance imaging [MRI] findings)
Known leptomeningeal disease or evidence of prior or current metastatic brain disease (routine screening with central nervous system [CNS] imaging studies [computed tomography (CT) or magnetic resonance imaging (MRI)] is required only if clinically indicated)
Must have presence of an enhancing solid renal mass =< 3.0 cm on computed tomography (CT) or magnetic resonance imaging (MRI)
Diagnostic imaging magnetic resonance imaging (MRI) and/or computed tomography (CT) of the area to be treated within 8 weeks of any treatment; baseline bone marrow biopsy and bone scan (with 99m-Tc-diphosphonate or metaiodobenzylguanidine [MIBG] scan [131I-MIBG or 123I-MIBG]) from time of original diagnosis is required
Clinically negative lymph nodes as established by imaging (pelvic ± abdominal computed tomography [CT] or magnetic resonance imaging [MRI]), (but not by nodal sampling, or dissection) within 90 days prior to registration
The subject has had an assessment of all known disease sites e.g, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Pancreas protocol computed tomography (CT) and/or magnetic resonance imaging (MRI) if required for further clarification of disease tissue planes within 4 weeks of registration
The subject has evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computerized tomography (CT) scan; subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible
Radiographic evidence of metastatic disease; computed tomography (CT) and bone scan must be performed with 21 days (+ 7 days) of registration; magnetic resonance imaging (MRI) of brain can be performed within 6 months prior to registration
Participants must have histologically or radiological evidence of stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Local, locally advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> 1.5 cm)
Contrast computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain negative for central nervous system metastases within 30 days of treatment
Magnetic resonance imaging (MRI) with gadolinium should be obtained within 21 days prior to beginning treatment; patients without measurable disease are eligible; participants must be able to undergo MRIs (computed tomography scans [CTs] are not allowed for response assessment on study)
Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).
Measurable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI)
At least one measurable viable tumor in the liver, ?1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)
Tumor volume occupies less than 50% of liver by volume as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) scan within 4 weeks of treatment
Evidence of distant metastasis; (determined by computed tomography [CT] scan, magnetic resonance imaging [MRI], and/or bone scan prior to the simulation appointment; imaging results from University of Pennsylvania Health System [UPHS] will supersede results from similar scans from an outside facility)
Patients must have an magnetic resonance imaging (MRI) or computed tomography (CT) of the head showing no central nervous system (CNS) metastases within 6 weeks of study entry
Must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI)
Confirmed presence of hepatocellular carcinoma indicated on computed tomography, magnetic resonance, or other imaging techniques within 3 months prior to screening
Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology.
Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)
High-quality cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) performed within 4 weeks prior to enrollment
No evidence of metastatic disease or nodal disease as determined by radionuclide bone scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological lymph nodes must be less than 20 mm in the short (transverse) axis.
At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
Must have measurable disease per RECIST 1.1 as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). a. Lesion/s deemed accessible to biopsy for both before and on-treatment biopsies.
Clinical T1N0M0 (=< 7 cm) renal mass as measured on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
? 5 metastases on conventional imaging with computed tomography (CT)/magnetic resonance imaging (MRI) of the abdomen/pelvis and whole body bone scan
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT]).
All patients must have measurable disease by imaging defined as tumor that can be measured >= 10 mm with multiparametric magnetic resonance imaging (MRI) (primary modality of imaging) or computed tomography (CT) (as an alternative) or >= 10 mm by caliper on physical examination
Measurable or evaluable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version (v)1.1
Patients must have localized disease with a primary tumor >= 5 cm by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by computed tomography (CT) or magnetic resonance imaging (MRI) scan, analysis of cerebrospinal fluid or neurological exam; patients with primary glioblastoma multiforme are excluded
Have been more than 1 month and less than 3 months after the completion of planned adjuvant chemotherapy and no definitive evidence of recurrent disease on screening imaging (computed tomography [CT] or magnetic resonance imaging [MRI]); if adjuvant treatment is not planned, then patients must be more than 1 month and less than 3 months after resection of their pancreas cancer
Computed tomography (CT) or magnetic resonance imaging (MRI) within 14 days prior to start of study therapy
Assessable disease with a positive bone scan and/or measurable disease on computed tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and pelvis
Must have measurable disease by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan; measurable disease is not necessary for inclusion
Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging (MRI) or PET imaging including contrast agents
Known contraindication to enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scan
Histologically confirmed cancer with measurable or evaluable brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI); MRI is preferred, but a CT scan is acceptable for patients that are unable to have an MRI
Unresectable by radiographic criteria (pancreas protocol computed tomography [CT] or magnetic resonance imaging [MRI]) or exploration within 30 days prior to registration
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
Patients will only be eligible for this trial if they have disease with tumor measurable on the computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 criteria.
Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
Any lesion invading or having encasement ? 180 degrees around the wall of a major blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the abdomen and chest; required only if aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or ALP is ?2 x ULN
>= 90% surgical resection of recurrent GBM confirmed by central radiology review by magnetic resonance imaging (MRI) with or without gadolinium per institutional guidelines; a computed tomography (CT) scan is allowable in place of MRI only in situations where an MRI is contraindicated (e.g., patient has a heart pacemaker, metallic devices in the eye, brain or spine, severe claustrophobia)
Radiological or clinical evidence (bone scan, computerized tomography [CT], and magnetic resonance Imaging [MRI]) of recurrence or progression within 30 days before randomization
Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1.
Measurable disease defined per RECIST v. 1.1, or bone-only disease must have a lytic or mixed lytic blastic lesion that can be accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Individuals with bone-only disease and blastic-only metastases are not eligible
Subject has one or more tumors measurable by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; magnetic resonance imaging (MRI) is acceptable if a CT scan is contraindicated
Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments
Has progression and measurable disease in the brain by magnetic resonance imaging (MRI) or computed tomography (CT)
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan
Bi-dimensionally measurable disease on cross sectional imaging by X-ray Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Known leptomeningeal involvement by lymphoma or current metastatic brain disease; routine screening with central nervous system (CNS) imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated
Patients with stage IV malignancy (non-mesothelioma) must have had a brain scan (magnetic resonance imaging [MRI] or computed tomography [CT] with contrast) showing no evidence of disease progression within 8 weeks of study enrollment
Complete clinical remission is defined as cancer antigen (CA)-125 within normal limits, examination and computed tomography (CT) or magnetic resonance imaging (MRI) without objective evidence of disease (non specific abnormalities are permitted on radiologic imaging)
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) that is accessible to biopsy
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 25 weeks prior to registration at very high risk of recurrence as determined by 2 or more of the following combinations:\r\n* cT3a/b\r\n* PSA >= 20\r\n* Gleason score 8-10\r\n* >= 33% core involvement\r\n* OR any patient with pelvic lymph node involvement >= 1 cm as determined by pelvic computed tomography (CT) or magnetic resonance imaging (MRI) imaging will meet eligibility criteria for enrollment
Evidence of lymph node or bone metastasis by magnetic resonance imaging (MRI)/computed tomography (CT), bone scan, or biopsy (N1Mx or NxM1)
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of study inclusion
World Health Organization (WHO) grade IV glioma with definitive resection prior to consent, with residual radiographic contrast enhancing disease on the post-operative computed tomography (CT) or magnetic resonance imaging (MRI) of < 1 cm in maximal diameter in any axial plane
The ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) based volume estimation of the patient’s prostate gland should be =< 80 grams\r\n* For patients with prostate size > 60 grams cytoreduction therapy with ADT is recommended
The subject has evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computed tomography (CT) scan; subjects with resolving hemorrhage, punctate hemorrhage, or hemosiderin are eligible
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain must be performed preoperatively and postoperatively (preferably within 96 hours of surgery), prior to the initiation of radiotherapy
Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician)
Metastatic diseases measurable or evaluable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to RECIST 1.1 criteria; locally recurrent disease that is not amenable to potentially curative surgery or radiation therapy is also allowed; lesions must be >= 10 mm in size; recurrent or metastatic disease within a prior radiation field is acceptable as long as the disease has progressed in the radiation field by RECIST criteria
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =< 28 days of study registration negative for disease recurrence
Evidence of metastatic disease by radiographic imaging (bone scan or other nodal or visceral lesions on computed tomography [CT] or magnetic resonance imaging [MRI])
Evidence of metastatic disease on previous bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Subject has measurable disease by radiographic techniques (computerized tomography [CT] or magnetic resonance imaging [MRI]);
Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (HCC) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of HCC by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT])
Presence of existing lytic bone lesions either by skeletal X-ray, computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
The patient must have post-operative contrast enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) unless only biopsy performed (in which case post-operative imaging is not routinely obtained; in these patients, the preoperative study will serve as baseline
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT), magnetic resonance imaging (MRI); if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
Prostate volume (by ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI] measurement) < 50 cc at time of enrollment
Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed < 30 days prior to registration) and complete neck exam from the skull base to the clavicles; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI); the primary tumor should be cT1 or T2 and cervical nodes cN1, N2a, or N2b based on clinical or radiographic criteria
Unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) with and without contrast and with perfusion (or computed tomography [CT] if MRI is contraindicated); the scan must be performed within 14 days of starting treatment
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Metastatic disease documented by one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI), or
Participants must have histologically or/and radiologically confirmed advanced hepatocellular carcinoma (HCC); radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria
Local, locally-advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) evidence of hemorrhage deemed significant by the treating physician (> grade 1); subjects with history of central nervous system (CNS) hemorrhage are not eligible
Radiographic evidence of spinal metastasis is required and may be obtained from radionuclide bone scans, computed tomography imaging, and magnetic resonance imaging; other studies may be used with principal investigator approval, but plain radiograph (X-ray) alone is not sufficient
Documented evidence of M1 disease by American Joint Committee on Cancer (AJCC) staging by bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI)
Metastatic disease on imaging (e.g., bone scan, computed tomography [CT], magnetic resonance imaging [MRI]); patients whose disease spread is limited to regional pelvic lymph nodes are not eligible; if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan; for leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable
If patients have small-volume disease the current study will be restricted to patients with minimal ascites not causing abdominal distention/mesenteric thickening or not requiring paracentesis, or lesions =< 5 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI) at baseline
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
Patients with known contraindication to magnetic resonance imaging (MRI), such as cardiac pacemaker, shrapnel, or ocular foreign body; however, head computed tomography (CT) with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant’s CNS lesions are clearly measurable on the head CT
A brain scan should be performed within 14 days prior to registration and steroid dosing should be stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/computed tomography (CT) is required; the same type of scan, i.e., magnetic resonance imaging (MRI) or CT must be used throughout the period of protocol treatment for tumor measurement
Primary disease > 7.5 cm in largest diameter as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
Treated (surgery, radiation therapy) but not clinically and radiographically stable 3 weeks after local therapy(as assessed by contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]), OR
Maximum tumor dimension of =< 6 cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography [CT], magnetic resonance imaging [MRI] or PET/CT) and considered amenable for radiation therapy (RT)
Inability to have neither a magnetic resonance imaging (MRI) nor a computed tomography (CT) scan; patients with a pacemaker must undergo CT instead of MRI to be eligible
Prostate size as determined on magnetic resonance imaging (MRI) to be < 90 cc; prostate size can be determined on computed tomography (CT) scan if MRI is not available
At least 1 lesion (measurable by RECIST v1.1) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment;
Diagnosis of HCC by biopsy-proven pathologic diagnosis or by clinical criteria as defined below: \r\n* Clinical criteria to be met if patient has a history of cirrhosis or chronic hepatitis B infection:\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by magnetic resonance imaging (MRI) or triple-phase computed tomography (CT) scan\r\n** Alpha-fetoprotein (AFP) of any value\r\n* Clinical criteria to be met if patient has no history of cirrhosis or chronic hepatitis B infection\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by MRI or triple-phase CT scan\r\n** And AFP > 20 mg/dL
No evidence of metastatic disease on physical exam, computed tomography (CT)/magnetic resonance imaging (MRI)/chest x-ray (CXR), and bone scan within 4 weeks prior to randomization
Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease; if no histologic confirmation, then the metastases or recurrence will require documentation by a 2nd radiographic procedure (eg. PET/computed tomography [CT] scan or magnetic resonance imaging [MRI] in addition to the CT scan); if the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required
Patients must have at least 1 evaluable lesion. Lesions must be evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
At least 1 node ? 2 cm on computed tomography (CT) or magnetic resonance imaging (MRI) or
Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma and they have evaluable or measurable disease by other (radiographic, magnetic resonance imaging [MRI], computed tomography [CT], lytic measurable lesion on x-ray,) means
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
Presence of metastatic disease (M1) as assessed by computed tomography/ magnetic resonance imaging (CT/MRI) and/or whole-body radionuclide bone scan.
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Hypersplenism documented by imaging study (ultrasound [US] or computed tomography [CT])
Patients with metastatic disease, target lesion must be measurable using computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have a patent portal vein as documented by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound
Imaging, a combination of at least two of the following (computed tomography [CT], magnetic resonance imaging [MRI], endoscopic ultrasound [EUS]) staging the pancreatic mass as “locally advanced”
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan.
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic, previously irradiated lesions are eligible provided participant is >/=4 weeks beyond completion of cranial irradiation and >/=3 weeks off of corticosteroid therapy
Patient with known but adequately treated brain metastases and without central nervous system (CNS) disease progression as determined by computed tomography (CT) or magnetic resonance imaging (MRI) imaging within 4 weeks of the first dose of study drug
Subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI)
Documented metastatic disease on bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI)
Appropriate diagnosis for protocol entry, based upon the following minimal diagnostic work-up:\r\n* History/physical examination within 8 weeks prior to registration and:\r\n* Suspicion of metastatic cancer to the vertebrae or multiple myeloma with a focus in a vertebral body(ies) and;  \r\n* The lesion must be identifiable with radiologic evidence (x-ray, bone scan, computed tomography [CT] scan, magnetic resonance imaging [MRI])
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not available) of the brain must be performed within 14 days prior to study entry
Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography (CT) or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last cancer therapy within 6 months prior to randomization.
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Brain lesion(s), if still present, must be confirmed stable (i.e., no increase in lesion size) for >= 6 weeks prior to randomization (stability must be confirmed with two consecutive magnetic resonance image (MRI) or computed tomography (CT) scans with contrast, AND
Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan
Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
Pre-operative computed tomography (CT)/magnetic resonance imaging (MRI) abdomen and pelvis within 90 days
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans
Subject has no contraindication for computed tomography (CT) and/or magnetic resonance imaging (MRI) during screening and is able to complete a screening examination; CT and/or MRI within 6 months of screening is required
Patients must have a diagnostic quality magnetic resonance imaging (MRI) of the brain or if contraindicated then contrast computed tomography (CT) scan of the head performed within 28 days prior to registration
Subjects must have at least one lesion that is not within a previously radiated field that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; if the subject’s only evaluable disease is within a previously radiated field, it must have demonstrated progression since the time of radiation
Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1
At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Subjects must have measurable disease by computed tomography (CT) scans or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to first dose of study drug
Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation
Patients with known bone metastases, with evidence of corticol bone damage/lytric lesions/blastic lesions on standard imaging studies (computed tomography [CT]/magnetic resonance [MR])
Radiographic (X-ray, or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
Metastatic bone disease with metastatic disease previously confirmed by prior biopsy; or Metastatic bone disease previously confirmed on imaging [e.g. computed tomography (CT) or magnetic resonance imaging (MRI)] with known (biopsied) primary disease (primary bone cancer is excluded)
Patients must have achieved a documented complete response to treatment based on normal cancer antigen (CA)-125 (per the institution’s upper limit of normal) and computed tomography (CT) scan or magnetic resonance imaging (MRI) with contrast (i.e. there must be no clinical evidence of persistent or recurrent disease based on CA-125 and CT scan or MRI with contrast)
Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception: If deemed clinically significant, then liver imaging must be available within previous 6 months (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI]) showing no evidence of hepatocellular carcinoma
Advanced chronic pancreatitis as determined by the following criteria: EUS score greater than 6, calcifications in combination with atrophy and/or dilation of >= 5 mm, or evidence of advanced chronic pancreatitis by computed tomography (CT) or magnetic resonance imaging (MRI) results in the past 12 months
Confirmed diagnosis of liver cirrhosis assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging [MRI]), or liver biopsy
Confirmed diagnosis of liver cirrhosis (Child-Pugh A or B) assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging (MRI), or liver biopsy
Subjects with bone dominant disease with at least 2 skeletal metastases identified at baseline by bone scintigraphy and confirmed by computed tomography (CT)/magnetic resonance imaging (MRI).
Patients with untreated focal liver observations on liver ultrasound or multiphase contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) performed as part of clinical standard of care within 4 weeks before patient enrollment
Undergone standard of care conventional imaging (computed tomography [CT] and/or magnetic resonance [MR]; bone scan and/or sodium fluoride [NaF] PET)
Have at least one kidney lesion identified but incompletely characterized on a non-contrasted ultrasound (US), computed tomography (CT), or magnetic resonance (MR) exam for which the patient’s provider recommends follow-up studies or further evaluation with an additional imaging tests.
PATIENT: Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT] or ultrasound [US]) in the 24 hours prior to the research US exam
For patients with organ confined renal tumors to be enrolled, the renal mass must be >= 1 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage T1a-T4 (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney
GROUPS 1, 2, AND 3: Group 2 participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
Measurable or evaluable disease, lesions that have not been previously radiated, with clinically indicated imaging evaluation performed within 4 weeks prior to study entry (computed tomography [CT], magnetic resonance imaging [MRI], fluorodeoxyglucose [FDG]-PET or bone scan); patients requiring concurrent radiation treatment are not eligible unless additional lesions that are not being irradiated and are assessable for targeting are present
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Primary or recurrent/metastatic lesion size >= 1.5 cm as determined by imaging studies (ultrasonography, mammography, computed tomography [CT] or magnetic resonance imaging [MRI]) or physical examination
Patients with at least 1 measurable tumor lesion as assessed by Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST 1.1.
Patients who received anti-tumor therapy after histopathologic transformation to glioblastoma must have shown unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan if MRI is contraindicated)
Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT], of US) in the 24 hours prior to the research US exam
Be scheduled for contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) to monitoring of RCC recurrence as part of their 8, 12, 18, 24, or 36 month CT/MRI follow up
Presence of at least one measurable or detectable metastasis as defined by bone scintigraphy, computed tomography (CT) scan appearance (magnetic resonance imaging [MRI] if indicated), or plain x-ray appearance
Patients must have radiographic evidence of upper tract urothelial cancer by computed tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in order to undergo this procedure
The lesion shows intratumoral arterial phase enhancement on contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
